Table 4.

Summary of fitted univariate Cox proportional hazards models for OS and progression-free survival (PFS)

		OS				PFS
	n	HR	Low 95%	High 95%	P	HR	Low 95%	High 95%	P
Race (w vs. not-w)	114	1.066	0.514	2.211	0.863	0.973	0.490	1.935	0.939
Mets.at.diagnosis	114	1.686	1.075	2.643	0.023	1.524	1.012	2.296	0.044
log.T.diag	114	0.842	0.734	0.965	0.014	0.832	0.729	0.950	0.007
No. of criteria = C1+….+C7	114	1.410	1.126	1.766	0.003	1.211	0.970	1.511	0.092
C1	114	1.564	0.981	2.493	0.060	1.354	0.860	2.131	0.191
C2	114	1.088	0.641	1.846	0.755	1.096	0.651	1.846	0.730
C3	114	1·230	0.693	2.182	0.479	1.362	0.786	2.362	0.271
C4	113	1.682	1.098	2.575	0.017	1.677	1.132	2.485	0.010
C5	114	1.013	0.616	1.666	0.960	0.710	0.438	1.148	0.163
C6	108	2.150	1.235	3.741	0.007	1.126	0.673	1.882	0.651
LDH > 546	114	2.834	1.837	4.375	<0.0001	2.472	1.645	3.714	<0.0001
CEA > 6	114	3.241	1.973	5.325	<0.0001	1.400	0.889	2.205	0.150
IHC (+ vs. –)	52	1.229	0.675	2.238	0.500	0.919	0.515	1.641	0.780
C7	114	0.796	0.525	1.206	0.281	0.859	0.581	1.270	0.446
GS ≥ 8	101	1.203	0.730	1.984	0.470	1.393	0.864	2.244	0.170
PS = 0	25				Ref.				Ref.
PS = 1	74	2.396	1.316	4.363	0.004	1.904	1.149	3.154	0.012
PS = 2	15	3.985	1.818	8.733	0.001	3.003	1.513	5.961	0.002
Age	114	1.003	0.977	1.029	0.822	0.994	0.973	1.016	0.618
log.ACTH	101	1.134	0.774	1.662	0.517	1.121	0.775	1.621	0.545
log.ADH	74	1.159	0.930	1.444	0.190	1.094	0.872	1.372	0.436
log.Alk	104	1.249	0.953	1.636	0.107	0.896	0.681	1.178	0.431
log.BS.Alk	108	1.292	1.040	1.605	0.021	1.002	0.815	1.233	0.983
log.Calcitonin	88	1.581	1.202	2.079	0.001	1.566	1.196	2.050	0.001
Calcium	113	0.683	0.439	1.064	0.092	1.039	0.694	1.557	0.851
log.CEA	113	1.523	1.325	1.752	<0.0001	1.263	1.083	1.474	0.003
log.ChrA-1	74	0.871	0.702	1.079	0.206	0.941	0.769	1.151	0.553
log.ChrA-2^a	35	1.630	1.010	2.610	0.045	1.200	0.803	1.789	0.375
log.GRP	57	0.791	0.501	1.247	0.313	0.794	0.537	1.173	0.247
Hb	114	0.804	0.709	0.912	0.001	0.915	0.817	1.025	0.127
log.LDH	114	2.714	1.698	4.340	<0.0001	2.570	1.693	3.901	0.0001
log.PAP	111	1.080	0.952	1.226	0.231	1.084	0.956	1.229	0.211
log.PSA	114	1.029	0.913	1.161	0.639	1.031	0.921	1.155	0.591
PSA DT	52	1.066	0.935	1.216	0.340	1.012	0.916	1.118	0.810
log.Somat	106	2.253	1.320	3.845	0.003	1.763	1.072	2.899	0.025
log.uNTX	61	1.404	0.970	2.031	0.072	0.986	0.699	1.392	0.936

Abbreviations: ACTH, adrenocorticotropic hormone; ADH, antidiuretic hormone; Alk, alkaline phosphatase; BS, bone-specific; C1–C7, eligibility criteria 1–7; ChrA-1, serum chromogranin A measured by Calbiotech chemiluminescence ELISA at Quest Diagnostics; ChrA-2, serum chromogranin A measured by homogeneous time-resolved fluorescence conducted at Mayo Medical Laboratories; DT, doubling time; GRP, gastrin-releasing peptide; GS, Gleason score; Hb, hemoglobin; IHC, immunohistochemistry; Mets, metastases; PS, performance status; Somat, somatostatin; T.diag., time from diagnosis; uNTX, urine N-telopeptides; w, white.

↵^aDuring the study, the method for measuring serum chromogranin A was changed in the MD Anderson laboratory from Calbiotech chemiluminescence ELISA at Quest Diagnostics to homogeneous time-resolved fluorescence conducted at Mayo Medical Laboratories.